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Summary
Background The prevalence of eczema, particularly in younger children,
increased substantially over the second half of the 20th century. Analysis of
primary healthcare data-sets offers the possibility to advance understanding
about the changing epidemiology of eczema.
Aim To investigate recent trends in the recorded incidence, lifetime
prevalence, prescribing and consulting behaviour of patients with eczema in
England.
Methods QRESEARCH is one of the world’s largest national aggregated
health databases containing the records of over nine million patients.We
extracted data on all patients with a recorded diagnosis of eczema and
calculated annual age–sex standardized incidence and lifetime period
prevalence rates for each year from 2001–2005.We also analysed the
consulting behaviour of these patients when compared with the rest of the
QRESEARCH database population.The number of eczema prescriptions
issued to people in England was also estimated.
Results The age–sex standardized incidence of eczema was 9.58 per 1000
person-years in 2001 and increased to 13.58 per 1000 patients in 2005
(p<0.001). By 2005, eczema affected an estimated 5,773,700 (95% confidence
intervals [CI] 5,754,100–5,793,400) individuals in England, who, on average,
consulted a general practitioner 4.02 (95% CI 4.01–4.03) times a year. During
the study period, the number of eczema related prescriptions increased by
56.6% (95% CI 56.6–56.7), so by 2005 an estimated 13,690,300 (95% CI
13,643,200–13,737,600) prescriptions were issued.
Conclusions Recorded incidence and lifetime prevalence of eczema in
England continue to increase. Similar increases have also been observed in
the estimated number of eczema prescriptions issued to the English
population.
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Introduction
A recent review of UK epidemiological data re-
vealed that there has been an inexorable rise in the
prevalence of allergic disorders.1 Allergic patho-
phyisiology can cause a spectrum of diseases in
individuals, whichmay vary in severity. Eczema is
an inflammatory skin disorder often resulting in
red, itchy and poorly{defined patches occurring on
flexural surfaces, and is most commonly found in
children of preschool age. Atopic eczema has
been defined as a chronic, relapsing, inflammatory
skin condition associated with epidermal barrier
dysfunction, which in turn is in many cases in-
creasingly believed to result from an underlying
filaggrin gene defect.2 Individuals can also exhibit
eczema without atopic features (i.e. non{atopic
eczema); such patients will respond to treatments
such as creams containing corticosteroids and
emollients just as well as individuals with atopic
eczema. Individuals with atopic eczema are how-
ever – unlike those with non{atopic eczema –more
likely to develop other atopic diseases such as
asthma or hayfever later in life,3 and their eczema
is often severe andmore likely to persist into adult-
hood.4
Survey data provide useful information on
variations in lifetime/period prevalence of self{
reported diagnoses of eczema, particularly in
children and adolescents. However there are
relatively few reliable national data describing cli-
nician{diagnosed disease incidence; furthermore
very few data exist on the overall population
trends over time for all ages. Exploitation of large
national healthcare data{sets, with their key
strengths of large numbers and representative
data, offers an important opportunity to develop
insights into the epidemiology of eczema.5 Study-
ing primary care databases provides a picture of
overall national trends – something that is not
possible with large scale surveys such as ISAAC,
which has studied only children,6 and the ECRHS,
which has surveyed only adults.7 Large primary
care data{sets such as QRESEARCH, recording in-
formation at the point at which the majority of
patients with eczema are likely to be managed, do
however offer an important opportunity to study
changing patterns of disease. Building on previous
work,8–10we sought to describe recent trends in the
primary care diagnosis, prescribing and consulting
behaviours of patients with eczema in England.
Methods
Version 10 of the QRESEARCH database was used
for these analyses. This database contains rep-
resentative anonymized aggregated health data
derived from 525 general practices throughout
England. Data were available for the period 1
January 1999 to 31 December 2005, these compris-
ing over nine million individual patients who
collectively contributed over 30 million patient{
years of observation. The methods used to collect
primary care data for the QRESEARCH database
have been previously described.8
Patients were included in the analysis year if
they were registered for the entire year of study.
Patients with incomplete data (i.e. temporary resi-
dents, newly-registered patients and those who
joined, left or died during the study year) were
excluded. Patients were considered to have
eczema if they had a relevant computer{recorded
diagnostic Read code in their electronic health
record during the time period of interest.
Incidencewas defined as the number of patients
with a new case of eczema diagnosed in a specific
year, with the denominator being the number of
patient{years of observation (calculated from the
number of patients registered with practices and
their length of registration). Lifetime prevalence
was defined as the number of people with eczema
ever recorded on at least one occasion in the
general practice records; the denominator used
to calculate the lifetime prevalence rate was
the number of patients registered with the study
practices.
In order to describe trends in prescribing of
eczema medication, we extracted prescribing data
and estimated numbers of eczema prescriptions
issued to all patients listed in chapters 13.2, 13.4
and 13.5 of the British National Formulary (emol-
lient and barrier preparations, topical steroids, and
psoriasis and eczema treatments). Although esti-
mated prescriptions issued to the whole English
population may equate with the numbers of pre-
scriptions dispensed nationally, these figures are
not directly comparable to Prescribing Analysis
and Cost Tabulation (PACT) data.
In order to compare our results on the rates and
trends of eczema in England with other published
data, a structured literature review was carried
out. We conducted our search using Medline and
Embase (from 1951 to December 2008), and also
with all co{authors
commenting on
drafts of the
manuscript
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Google Scholar. The search terms used included:
eczema, trends, prevalence and incidence.
Definitions
Eczema was defined as patients who have Read
codes M11 and below and M12z and below (see
Box 1 for Read codes used).
Statistical methods
As a result of known age and sex variations, rates
of disease and prescribing were standardized by
sex and five{year age bands. The mid{year popu-
lation estimates for England in each year of study
were used as the reference population. These
results were then used to estimate the numbers
of people with eczema in England. The Mantel{
Haenszel 2 test was used to investigate trends
over time, this analysis being undertaken using
EpiInfo2000 (World Health Organization, Geneva,
Switzerland).
Results
Incidence rate of eczema and changes
over time
During the five{year study period the number of
incident cases per 1000 population increased by
41.8% (p<0.001; Table 1). In 2005, approximately 1
in every 74 people in England was newly diag-
nosed as having eczema.
Age–sex standardization of lifetime
prevalence of patients with eczema and
changes over time
Between 2001 and 2005, there was a significant
increase in the number of registered patientswith a
diagnosis of eczema at some point in their lives
(Figure 1). The age–sex standardized lifetime
prevalence rate of eczema increased for the whole
population over each of the five years of interest,
with an overall 48.2% increase (p<0.001; Table 2).
In 2005, eczema affected an estimated 5,773,700
(95% confidence intervals [CI] 5,754,100–5,793,400)
or about 1 in 9 people in England. It was more
common in girls/women than in boys/men, ex-
cept in children aged under five years or those
aged over 75 years. In 2005, the highest lifetime
prevalence rate occurred in boys aged 5–9 years
(Figure 1).
Consultation rates for any reason for
patients with eczema
Table 3 compares general practitioner (GP) and
nurse consultation rates for patients with eczema.
Figure 2 compares overall consultation rates for
the whole QRESEARCH population with those for
patients with eczema broken down by age and sex.
This includes all GP and nurse consultations in
2005, regardless of the reason for the encounter.
Consultation rates for women tended to be higher
Table 1
Incidence of eczema
Year Age–sex standardized lifetime incidence
rate per 1000 patient{years
95% CI
2001 9.58 9.46–9.70
2002 10.40 10.28–5.30
2003 11.62 11.49–11.52
2004 13.38 13.24–13.52
2005 13.58 13.45–13.72
Box 1
Eczema Read codes used in the analysis
Read codes Read term
M11 Atopic dermatitis and related conditions
M110 Napkin dermatitis
M1100 Candidal nappy rash
M111 Atopic dermatitis/eczema
M112 Infantile eczema
M113 Flexural eczema
M114 Allergic (intrinsic) eczema
M115 Besnier’s prurigo
M116 Neurodermatitis – diffuse
M117 Neurodermatitis – atopic
M118 Infantile seborrhoeic dermatitis
M1180 Infantile seborrhoeic dermatitis capitis
M118z Infantile seborrhoeic dermatitis NOS
M119 Discoid eczema
M11z Atopic dermatitis NOS
M12z Contact dermatitis NOS
M12z0 Dermatitis NOS
M12z1 Eczema NOS
M12z2 Infected eczema
M12z3 Hand eczema
M12z4 Erythrodermic eczema
M12zz Contact dermatitis NOS
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than for men, and consultation rates for patients
with eczemawere higher than overall consultation
rates. For example, for men aged 85–89 years, the
GP and nurse consultation rate for patients with a
diagnosis of eczema was 1.3 times higher than the
corresponding overall consultation rate in that
group of patients.
Figure 3 shows consultation rates per patient
(regardless of the reason for the consultation) for
eczema broken down by age and sex. The highest
consultation rate occurred in women aged 85–89
years.
Prescriptions for eczema treatments
Table 4 shows the estimated number of eczema
prescriptions issued to thewhole population in the
years 2001 to 2005. Overall there was an increase
of 56.6% (95% CI 56.6–56.7) in the number of pre-
scriptions issued (emollient and barrier prepara-
tions increase: 78.7% (95% CI 78.6–78.7); topical
corticosteroids: 36.4% (95% CI 36.3–36.4); and
psoriasis and eczema: 20.7% (95% CI 20.7–20.8)).
Discussion
This study, using routine data from one of the
world’s largest national data{sets, has revealed
that eczema occurs very commonly in children
and adults, and that, in the beginning of the new
millennium, a large increase has occurred in the
recorded incidence and lifetime prevalence (in all
Table 2
Lifetime prevalence of eczema
Year Age–sex standardized lifetime prevalence
rate per 1000
95% CI
2001 77.78 77.46–78.11
2002 85.96 85.62–86.30
2003 95.14 94.78–95.50
2004 105.50 105.13–105.88
2005 115.26 114.87–115.65
Figure 1
Lifetime prevalence of eczema per 1000 patients
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ages) of these problems. The number of consulta-
tions for eczema and eczema-related prescriptions
issued in primary care in England has also in-
creased during the study period. The consultation
rate also seemed to be higher than the overall
population and persisted into adulthood, when, in
the majority of cases, eczema is no longer likely to
be as problematic.
Main strengths and limitations of this
work
The main strengths of this study include our inter-
rogation of an extremely large nationally represen-
tative data{set, the fact that all contributing
practices used the same computing systems for
electronically recording clinical data, and the ap-
proach used to ensure that all contributing prac-
tices were accustomed to electronically recording
routine data. The study design employed ensured
that there was no risk of selection bias due to non{
responders or recall bias. Another strength of this
study was the use of contemporaneous clinician
recording of a diagnosis of eczema as opposed to
patient self{reporting of historical diagnoses or
symptoms.6,7
There are a number of limitations related to the
use of large routinely collected data from primary
care, including the dependence on clinician{
recorded diagnosis of eczema and possible im-
provements in recording over the study time
Table 3
Consultation rates for eczema patients per person per year by
clinician by year
Year Age–sex standardized consultation rate per person
per year (95% confidence intervals)
General practitioner Nurse
2001 3.77(3.76–3.78) 1.22(1.21–1.22)
2002 3.83(3.82–3.83) 1.35(1.35–1.36)
2003 3.94(3.93–3.95) 1.47(1.46–1.47)
2004 4.01(4.00–4.02) 1.53(1.52–1.53)
2005 4.02(4.01–4.03) 1.62(1.61–1.62)
Figure 2
Overall consultation rates compared with those for eczema, for all GP and nurse consultations in 2005
Journal of the Royal Society of Medicine
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period. The relatively short time window over
which trends were studied is another limitation,
but this does also have the advantage of confining
analysis to a period during which there were no
changes in disease definition or classification. Data
regarding childhood prevalence may be under-
estimated, as the ascertainment of disease present
in the community will be dependent on parents
bringing their children for consultation.11 Under-
estimates of eczema prevalence have been com-
pounded by some individuals with mild disease
not consulting, opting to use either no treatment
or over{the{counter preparations. The inadequacy
of Read codes for allergy has been previously re-
ported12 and although it is difficult to quantify the
precise effect of this, it is likely to have contributed
to an underestimate in relation to the actual popu-
lation prevalence of eczema. However this inad-
equacy is unlikely to have had any effect on the
increasing trends of eczema, as no changes in Read
codes for eczema have been introduced during the
study period.
Comparison of findings with other
published work
Table 5 compares previous published epidemio-
logical data for eczema. We have found using data
from our work that the lifetime clinician{recorded
prevalence peaks in younger children mirrored
results from a birth cohort,13 and the prevalence
in our older adults was similar to that found in
survey data.7 Although little data on the trend of
eczema prevalence exist prior to World War II
(1939–1945), the prevalence of eczema increased
substantially in the latter half of the 20th century,
with eczema in school{aged children being found
to increase between the late 1940s and 2000.14–16
In contrast to our results, survey studies (see Box 2
Figure 3
Overall GP consultation rates (regardless of the reason for the consultation) for patients with eczema in
2001 and 2005
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for questions used in surveys) from the period
immediately prior (1995–1996 to 2000–2001)17
and intersecting our study period (1995–1996
to 2002–2003)6 found only a moderate increase
in eczema in children (2–15 years), a decrease in
older children (13–14 years) and no increase in
adults (aged >15 years) over time. Also in contrast
to our data, a study using general practice elec-
tronic data which intersected our study period
(1995–2004) found a steep decline over time
in young children (<5 years) presenting with
eczema,18 but similar to our study found increases
in adults (>45 years).
Meaning of the study results: possible
mechanisms and implications for
clinicians and policy{makers
There may be several possible reasons for the in-
creases in eczema diagnosis found inQRESEARCH.
One possible explanation is that changes in en-
vironmental factors over time have favoured the
Table 4
Total estimated count of eczema-related prescriptions for all people in England
Year Prescription Estimated number
of prescriptions in
England
95% confidence
intervals
2001 Emollient and Barrier Preparations (BNF chapter 13.2) 4,267,300 4,249,700–4,285,000
Topical Corticosteroids (BNF chapter 13.4) 4,271,700 4,254,500–4,289,000
Psoriasis And Eczema (BNF chapter 13.5) 200,200 196,600–203,900
2002 Emollient and Barrier Preparations (BNF chapter 13.2) 4,841,300 4,822,600–4,860,000
Topical Corticosteroids (BNF chapter 13.4) 4,543,500 4,525,800–4,561,200
Psoriasis And Eczema (BNF chapter 13.5) 208,100 204,400–211,800
2003 Emollient and Barrier Preparations (BNF chapter 13.2) 5,621,000 5,600,900–5,641,100
Topical Corticosteroids (BNF chapter 13.4) 4,923,000 4,904,700–4,941,400
Psoriasis And Eczema (BNF chapter 13.5) 180,200 176,800–183,700
2004 Emollient and Barrier Preparations (BNF chapter 13.2) 6,666,300 6,644,300–6,688,300
Topical Corticosteroids (BNF chapter 13.4) 5,532,300 5,512,800–5,551,900
Psoriasis And Eczema (BNF chapter 13.5) 216,900 213,200–220,800
2005 Emollient and Barrier Preparations (BNF chapter 13.2) 7,623,900 7,600,600–7,647,300
Topical Corticosteroids (BNF chapter 13.4) 5,824,700 5,804,800–5,844,600
Psoriasis And Eczema (BNF chapter 13.5) 241,700 237,800–245,700
Box 2
Questions used in surveys to measure eczema prevalence
Survey Question used
The International Study of Asthma and Allergies in
Childhood
Have you (has your child) ever had a skin rash
which was coming and going for at least 6 months?
Have you (has your child) had this itchy rash at any
time in the past 12 months? Has this itchy rash at
any time affected any of the following places: the
folds of the elbows; behind the knees; in front of
the ankles; under the buttocks; or around the neck,
ears or eyes?
The Health Survey for England Have you ever had eczema?Was this confirmed by
a doctor?
The European Community Respiratory Health
Survey
Have you ever had eczema or any kind of skin
allergy?
The Aberdeen School Children Questionnaire Have you ever had eczema?
Journal of the Royal Society of Medicine
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expression of allergic disease in those who are
genetically susceptible.2,19,20 There may also have
been increases in sensitization over time, which
may then in turn predispose the development of
any of a number of allergic disorders. Supporting
evidence for such a possibility comes from an
important study by Law et al., which found signifi-
cant increases in atopic sensitization in the UK
over a 25-year window.21 Increased predisposition
to atopy,22 possibly reflecting changing exposure
to known and unknown risk factors,23 may also be
important. Increases in the rate of these conditions
could however result from increased clinician
awareness of allergic problems, which may then
have led to improved identification and recording
of eczema. Similarly, increased patient awareness,
or parental awareness of the potential of access-
ing effective treatments, may have resulted in
increased case presentation and prescribing in
primary care.
Given the high prevalence of eczema, particu-
larly in younger children when compared with
adults, the overall numbers of people in England
with eczema is, for the present at least, likely to
continue to increase. A key related important
unanswered question concerns the quality of care
and symptom control for parents and carers of
younger children,24 particularly as eczema is most
symptomatic at this younger age and is likely to
herald the onset of other allergic conditions.25
Efforts must therefore be directed into investigat-
ing effective methods of primary prevention and
symptom control, particularly as high levels of
consultation rates for this growing population will
persist into older age, with an associated substan-
tial impact on the NHS, and in particular primary
care. The House of Lords Allergy Inquiry pub-
lished in 2007 has identified several issues high-
lighted by this work and other previous research
that require further attention.26
Conclusions and future research
This large national study reveals that the recorded
incidence and lifetime prevalence of patients with
eczema increased in England. With almost 1 in 9 of
the population having experienced the condition
at some point in their lives, eczema is now one of
the most common chronic conditions to effect the
English population, and therefore continuingmoni-
toring of trends is very important. Whether these
findings reflect a genuine increase in the incidence
of eczema, improved awareness, diagnosis and re-
cording in primary care, or, perhaps most plausibly,
a combination of genuine increases and improved
identification and recording, is a question with
important public health implications and one
therefore that warrants detailed further enquiry.
References
1 Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of
allergic disease in the UK: secondary analyses of national
databases. Clin Exp Allergy 2004;34:520–6
2 Simpson CR, Sheikh A. The filaggrin gene mutation,
atopic dermatitis and asthma. Prim Care Resp J
2007;16:322–4
3 European Academy of Allergy & Clinical Immunology.
See http://www.eaaci.org/allergydefinitions/english.htm
(last accessed 10 April 2008)
4 Brown S, Reynolds NJ. Atopic and non{atopic eczema.
BMJ 2006;332:584–8
5 Anandan C, Simpson CR, Fischbacher C, Sheikh A.
Exploiting the potential of routine data to better
understand the disease burden posed by allergic
disorders. Clin Exp Allergy 2006;36:866–71
6 The International Study of Asthma and Allergies in
Childhood (ISAAC) Steering Committee. Worldwide
variation in prevalence of symptoms of asthma, allergic
rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet
1998;351:1225–32
7 Harrop J, Chinn S, Verlato G. Eczema, atopy and allergen
exposure in adults: a population{based study. Clin Exp
Allergy 2007;37:526–35
8 Sheikh A, Hippisley{Cox J, Newton J, Fenty J. Trends in
national incidence, lifetime prevalence and adrenaline
prescribing for anaphylaxis in England. J Roy Soc Med
2008;101:139–43
9 Ghouri N, Hippisley{Cox J, Newton J, Sheikh A. Trends in
the epidemiology and prescribing of medication for
allergic rhinitis in England. J Roy Soc Med 2008;101:466–72
10 QRESEARCH and the Information Centre for health and
social care. Primary care epidemiology of allergic
disorders: analysis using QRESEARCH database 2001–6.
2007 See http://www.ic.nhs.uk/webfiles/publications/
allergdisorder/HSCICallergiesreportfromQRESEARCH
June2007[1].pdf (last accessed 10 May 2008)
11 McKeever TM, Lewis SA, Smith C, Collins J, Heatlie H,
Frischer M. Early exposure to infections and antibiotics
and the incidence of allergic disease: A birth cohort study
with the West Midlands General Practice Research
Database. J Allergy Clin Immunol 2002;109:43–50
12 Simpson CR, Anandan C, Fischbacher C, Lefevre K,
Sheikh A. Will SNOMED{CT improve our understanding
of the disease burden posed by allergic disorders? Clin
Exp Allergy 2007;37:1586–93
13 Arshad SH, Tariq SM, Matthews S, Hakim E. Sensitization
to common allergens and its association with allergic
disorders at age 4 years: a whole population birth cohort
study. Pediatrics 2001;108:E33
14 Taylor B, Wadsworth J, Wadsworth M, Peckham C.
Changes in the reported prevalence of childhood eczema
since the 1939–45 war. Lancet 1984;2:1255–7
15 Devenny A, Wassall H, Ninan T, Omran M, Khan SD,
Russell G. Respiratory symptoms and atopy in children in
Journal of the Royal Society of Medicine
J R Soc Med 2009: 102: 108–117. DOI 10.1258/jrsm.2009.080211116
Aberdeen: questionnaire studies of a defined school
population repeated over 35 years. BMJ 2004;329:489–90
16 Royal College of General Practitioners, Department of
Health and Office of Population Censuses and Surveys.
Morbidity Statistics from General Practice 1971–2, 1981–2,
1991–2, Studies on Medical and Population Subjects No
26, and Series MB5, Nos:1 and 3. London: OPCS
17 Bajekal M, Primatesta P, Prior G, eds. Health Survey for
England 2001. London: The Stationery Office; 2003
18 Gupta R, Sheikh A, Strachan D, Anderson HR. Time
trends in allergic disorders in the UK. Thorax 2007;62:91–6
19 MacLean JA, Eidelman FJ. The genetics of atopy and
atopic eczema. Arch Dermatol 2001;137:1474–6
20 Graves PE, Siroux V, Guerra S, Klimecki WT, Martinez FD.
Association of atopy and eczema with polymorphisms in
T{cell immunoglobulin domain and mucin domain –
IL-2–inducible T{cell kinase gene cluster in chromosome
5q33. J Allergy Clin Immunol 2005;116:650–6
21 Law M, Morris JK, Wald N, Luczynska C, Burney P.
Changes in atopy over a quarter of a century, based on
cross sectional data at three time periods. BMJ
2005;330:1187–8
22 Tariq SM, Matthews SM, Hakim EA, Stevens M, Arshad
SH, Hide DW. The prevalence of and risk factors for atopy
in early childhood: a whole population birth cohort study.
J Allergy Clin Immunol 1998;101:587–93
23 Mosges R, Klimek L. Today’s allergic rhinitis patients are
different: new factors that may play a role. Allergy
2007;62:969–75
24 Sheikh A, Khan{Wasti S, Price D, Smeeth L, Fletcher M,
Walker S. Standardized training for healthcare
professionals and its impact on patients with perennial
rhinitis: a multi{centre randomized controlled trial. Clin
Exp Allergy 2007;37:90–9
25 Simpson CR, Newton J, Hippisley{Cox J, Sheikh A.
Incidence and prevalence of multiple allergic disorders
recorded in a national primary care database. J Roy Soc
Med 2008;101:558–63
26 House of Lords Science and Technology Committee. 6th
Order of Session. Allergy – Volume I: Report. London: The
Stationery Office; 2007. See http://www.parliament.uk/
parliamentary_committees/lords_s_t_select/allergies.cm
(last accessed 24 February 2008)
Trends in the epidemiology and prescribing of medication for eczema in England
J R Soc Med 2009: 102: 108–117. DOI 10.1258/jrsm.2009.080211 117
